SEC Charges Clinical Drug Trial Investigator With Insider Trading

<p><span>The Securities and Exchange Commission today announced charges against Daniel V.T. Catenacci for insider trading in the securities of biotechnology company Five Prime Therapeutics, Inc. in advance of the company&rsquo;s November 10, 2020 announcement that it had achieved positive drug trial results for its flagship cancer drug Bemarituzumab.</span></p>

Related Keywords

Illinois ,United States ,Chicago ,San Francisco ,California ,Erine Schneider ,Daniel Vt Catenacci ,David Zhou ,Madiham Zuberi ,Moniquec Winkler ,Johns Rymas ,Exchange Commission ,Bureau Of Investigation ,Detection Center ,Therapeutics Inc ,Financial Industry Regulatory Authority ,Federal Bureau Of Investigation ,San Francisco Regional Office ,Five Prime Therapeutics ,Five Prime ,Regional Director ,Francisco Regional ,Northern District ,Market Abuse Unit ,Federal Bureau ,Financial Industry Regulatory ,Americas ,Eneral ,Regulation ,